New phase 3 data confirm prior positive findings of delgocitinib for chronic hand eczema

The DELTA 2 pivotal phase 3 clinical trial showed positive topline results for the use of delgocitinib cream in adults with moderate to severe chronic hand eczema, LEO Pharma announced in a press release.

These data confirm the findings of the DELTA 1 trial, which was completed in 2022 and showed near identical results in 487 adults with chronic hand eczema (CHE).

“It is incredibly exciting to see the level of consistency that our DELTA 2 results show in line with the positive DELTA 1 results announced late last year,” Jörg Möller, executive vice president of global research & development at LEO Pharma, said in the release. “CHE is a condition that we know can have a hugely negative impact on patient quality of life, physical functioning and ability to work. These results bring us one step closer towards establishing delgocitinib as a best-in-class innovative topical treatment for patients affected by this hard-to-treat disease.”

According to the release, the trial met its primary endpoint with patients exhibiting significant improvement after 16 weeks of treatment with delgocitinib, an investigational topical pan-Janus kinase (JAK)-inhibitor, compared with vehicle. During the early rounds of treatment, signs and symptoms were cleared or almost cleared in a greater portion of delgocitinib-treated patients vs. vehicle-treated patients. Additionally, the drug was well tolerated by participants.

Participants who completed 16 weeks of treatment in either DELTA 1 or DELTA 2 can now take part in the DELTA 3 trial, which will evaluate the long-term effects of delgocitinib cream.